Biothorpe was founded in 2008 and formed as a subsidiary of ZaBeCor Pharmaceuticals, a clinical stage biotechnology company focused on the development of siRNA, oligonucleotides and other molecular technologies for the treatment of asthma, allergies and other inflammatory and infectious diseases. Biothorpe was formed to build upon the research and development of ZaBeCor and to apply ZaBeCor’s patented technology to cancer therapeutics.
Biothorpe’s patents were developed by Alan D. Schreiber, M.D., a leading hematologist and oncologist and Assistant Dean of Research and Professor of Medicine at the University of Pennsylvania School of Medicine and the director of a large, well-funded immunology laboratory. Dr. Schreiber, Biothorpe’s Founder, Chairman and Chief Executive Officer, is an internationally-recognized authority on white cell and macrophage function who has published more than 200 scientific articles and authored all the Company’s patents, all of which have been exclusively licensed to Biothorpe from ZaBeCor.